Phase 4 N=70 Vascular Inflammation in Psoriasis - Apremilast
Psoriasis · Cardiovascular Diseases
Primary: Change in Total Vascular Inflammation of the Aorta as Measured by FDG-PET/CT Between Baseline and Week 16. — -0.017 ratio — p=0.612
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=43 Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -0.1015; 0.1442; -0.0151 TBR max — p=0.0012
Phase 3 N=58 Inflammation and Vascular Function in Atherosclerosis
Atherosclerosis
Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation
Phase 2 N=52 Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
Acute Coronary Syndrome
Primary: Change From Baseline in Plaque Imaging After 24 Weeks — -0.01; -0.06 TBR — p=0.34
N/A N=9 Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes
Pre-Eclampsia · Pre-Term · Intrauterine Growth Restriction
Primary: Blood Pressure (mmHg) — 122; 116 mmHg
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
Phase 2 N=191 Study Effect of VIA-2291 on Vascular Inflammation
Coronary Artery Disease
Primary: Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood — -88126; -95703; -122668; -20843 pg/mL — p=<0.001
Phase 3 N=123 Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Vascular Inflammation · Atherosclerotic Cardiovascular Disease
Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change
Phase 2 N=50 Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy
Atherosclerosis
Primary: Percent Cross-sectional Area of Macrophages in Plaque Tissue — 8.08; 8.19 Percent Area — p=0.97
Phase 4 N=97 Vascular Inflammation in Psoriasis Trial (The VIP Trial)
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -.067; -.052; -.079 Tissue-to-background ratio (TBR) — p=0.795
Phase 4 N=81 Vascular Inflammation in Psoriasis - Extension Study
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -3.8 percentage change
Phase 4 N=26 The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
Heart Failure · Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Flow-Mediated Dilation (FMD) — 3.61; 3.66; 4.22; 3.55 % increase from pre-occlusion value
Early Phase 1 N=23 Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
Preeclampsia
Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance
Phase 4 N=42 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)
Renal Insufficiency, Chronic
Primary: Change in Flow-mediated Dilation (FMD) — 1.1; -0.9 change in percent flow-mediated dilation
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
N/A N=74 Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Primary: Coronary Flow Reserve — 2.65 ratio
Phase 3 N=179 Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
Type 2 Diabetic Patients
Primary: Change in Post-ischemic Forearm Blood Flow — 3.60; 1.00 ml/100ml — p=0.004
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Phase 2 N=24 Etanercept and Vascular Function in Psoriasis
PSORIASIS
Primary: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD) — 9.71; 11.15 percentage of brachial artery diameter
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
Phase 4 N=91 Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Aortic Vascular Inflammation as Measured by FDG-PET/CT — 1.6615; 1.6333; 0.0143; 0.0655 target to background ratio (TBR) — p=0.3712
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
N/A N=89 Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
HIV Infection
Primary: Endothelial Function (Brachial Artery Reactivity) — 3.98; 3.37 percent dilation — p=0.10
Phase 2 N=81 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Coronary Artery Disease · Human Immunodeficiency Virus
Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement
Phase 2 N=110 A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
HIV-1-infection · Elevated Cardiovascular Risk
Primary: Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel. — 0.95…
Phase 2 N=43 Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
HIV · Cardiovascular Disease
Primary: Change in CD4 Count From Baseline to Follow-up — -0.085; -0.024; -0.020; -0.090 log cells per mm^3